[1]
Hirtz D., Thurman D.J., Gwinn-Hardy K. et al.: How common are the
“common” neurologic disorders?: Neurology 2007; 68: 326–337.
[2]
Téllez-Zenteno J.F., Hernández-Ronquillo L., Buckley S. et al.: A validation
of the new definition of drug-resistant epilepsy by the International
League Against Epilepsy. Epilepsia 2014 Jun;55(6): 829–834.
[3]
Pitkänen A., Löscher W., Vezzani A. et al.: Advances in the development
of biomarkers for epilepsy.: Lancet Neurol 2016; 15: 843–856.
[4]
Strimbu K., Tavel J. A.: What are Biomarkers?: Curr Opin HIV AIDS. 2010;
5(6): 463–466.
[5]
Fisher R.S., Acevedo C., Arzimanoglou A. i wsp.: A practical clinical
definition of epilepsy: Epilepsia 2014; 55: 475–482.
[6]
Rakhade S. N., Jensen F. E.: Epileptogenesis in the immature brain:
emerging mechanisms: Nat Rev Neurol 2009; 5: 380–391.
[7]
Barker-Haliski M. L., Friedman D., French J.A. et al.: Disease Modification
in Epilepsy: From Animal Models to Clinical Applications: Drugs 2015;
75: 749–767.
[8]
Jóźwiak S. Becker A., Cepeda C. et al.: WONOEP appraisal: Development
of epilepsy biomarkers-What we can learn from our patients?, Epilepsia
2017 Jun;58(6):951–961. doi: 10.1111/epi.13728. Epub 2017 Apr 7.
[9]
van Vliet E. A., Dedeurwaerdere S., Cole A.J. et al.: Workshop on
neurobiology of epilepsy appraisal: Imaging biomarkers in epilepsy;
Epilepsia 2016: 1–16.
[10]
Labete A., Cherubini A., Tripepi G. et al. White matter abnormalities
differentiate severe from benign temporal lobe epilepsy: Epilepsia 2015;
56: 1109–1116.
[11]
Tenney J.R., Duong T.Q., King J.A. et al. fMRI of brain activation in
a genetic rat model of absence seizures. Epilepsia 2004; 45: 576–582. 52.
[12]
Meeren H.K., Pijn J.P.M., Van Luijtelaar E.L.J.M., et al.: Cortical focus
drives widespread corticothalamic networks during spontaneous
absence seizures in rats. J Neurosci 2002; 22: 1480–1495.
[13]
Choy M. Dubé C.M., Patterson K., et al.: A Novel, Noninvasive, Predictive
Epilepsy Biomarker with Clinical Potential.: J Neurosci 2014; 34: 8672–
8684.
[14]
Jóźwiak S., Kotulska K., Domańska-Pakieła D., et al.: Antiepileptic
treatment before the onset of seizures reduces epilepsy severity and risk
of mental retardation in infants with tuberous sclerosis complex. Eur J
Paediatr Neurol 2011; 15: 424–431.
[15]
Wu J. Y., Peters J.M., Goyal M. et al: Clinical Electroencephalographic
Biomarker for Impending Epilepsy in Asymptomatic Tuberous Sclerosis
Complex Infants: Pediatr Neurol. 2016; 54: 29–34.
[16]
Thompson K., Pohlmann-Eden B., Campbell L.A. et al.: Pharmacological
treatments for preventing epilepsy following traumatic head injury.
Cochrane Database Syst Rev 015:CD009900.
[17]
Bragin A., Li L., Almajano J. et al.: Pathologic electrographic changes
after experimental traumatic brain injury. Epilepsia 2016; 57: 735–745.
[18]
Wang J., Yu J.T., Tan L. et al.: Genome-wide circulating microRNA
expression profiling. indicates biomarkers for epilepsy; Sci Rep 2015; 5:
9522: 1–9.
[19]
Chang C.C., Lui C.C., Lee C.C. et al.: Clinical significance of serological
biomarkers and neuropsychological performances in patients with
temporal lobe epilepsy; BMC Neurol 012; 12:15: 1–10.
[20]
Stocklin B., Fouzas S., Schillinger P. et al.: Copeptin as a serum biomarker
of febrile seizures PLoS ONE 2015;10(4):e0124663.
[21]
Diamond M.L., Ritter A.C., Failla M.D. et al.: IL-1beta associations with
posttraumatic epilepsy development: a genetics and biomarker cohort
study; Epilepsia 2014; 55(7): 1109–1119.
[22]
Mao L.Y., Ding J., Peng W.F. et al. Interictal interleukin-17A levels
are elevated and correlate with seizure severity of epilepsy patients;
Epilepsia 2013; 54(9): 142–145.
[23]
Lehtimaki K.A., Liimatainen S., Peltola J. et al.: The serum level of
interleukin-6 in patients with intellectual disability and refractory
epilepsy. Epilepsy Res 2011; 95(1–2): 184–187.
[24]
Riikonen R.S., Jääskeläinen J., Turpeinen U. et al.: Insulin-like growth
factor 1 is associated with cognitive outcome in infantile spasms.
Epilepsia 2010; 51(7): 1283–1289.
[25]
Hulkkonen J., Koskikallio E., Rainesalo S., et al.: The balance of inhibitory
and excitatory cytokines is differently regulated in vivo and in vitro
among therapy resistant epilepsy patients; Epilepsy Res 2004; 59(2–3):
199–205.
[26]
Vanhatalo S., Riikonen R.; Nitric oxide metabolites, nitrates and nitrites
in the cerebrospinal fluid in children with west syndrome. Epilepsy Res
2001; 46(1): 3–13.
[27]
Pollard J.R., Eidelman O., Mueller G.P. et al.: The TARC/sICAM5 ratio in
patient plasma is a candidate biomarker for drug resistant epilepsy; Front
Neurol 2012; 3: 181:1–8.
[28]
Walker L. E., Janigro D., Heinemann U. et al.: WONOEP appraisal:
Molecular and cellular biomarkers for epilepsy, Epilepsia. 2016; 57(9):
1354–1362.
[30]
http://epilepsydesireproject.eu/
[31]
https://www.epimirna.eu/
[32]
https://www.epitarget.eu/
Scholar Google
PubMed